Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4449053 | 0.98 | MAPT (0.42) | MAPTALDH1A1HRH3 | |
| SCHEMBL7902433 | 0.89 | ALDH1A1 (0.42) | MAPTALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL7123281 | 0.87 | ALDH1A1 (0.41) | MAPTALDH1A1HRH3 | |
| SCHEMBL13926499 | 0.87 | TMEM97 (0.39) | MAPT | |
| SCHEMBL713426 | 0.84 | MAPT (0.55) | MAPTHRH3 | |
| SCHEMBL611367 | 0.82 | MAPT (0.61) | MAPTALDH1A1HRH3 | |
| SCHEMBL9989362 | 0.82 | MAPT (0.40) | MAPTALDH1A1HRH3 | |
| SCHEMBL14889187 | 0.81 | MAPT (0.54) | MAPTHRH3 | |
| SCHEMBL21407969 | 0.81 | MAPT (0.46) | MAPTHRH3 | |
| SCHEMBL21407976 | 0.81 | MAPT (0.42) | MAPTALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090162314-A1 | Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia | GENZYME CORPORATION | 2009-06-25 | — | — | US | disclosed |
| EP-1945196-A2 | MAGNESIUM-CONTAINING POLYMERS FOR HYPERPHOSPHATEMIA | Genzyme Corporation (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056405-A2 | MAGNESIUM-CONTAINING POLYMERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA | GENZYME CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162314-A1 | Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia | PPIP5K2, PHPT1, PHOSPHO1 | MAPT 348/4885ALDH1A1 4615/4885HRH3 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.